These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 35730869)
1. Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster. Silva ARD; Villas-Boas LS; Paula AV; Tozetto-Mendoza TR; Honorato L; Witkin SS; Mendes-Correa MC Rev Inst Med Trop Sao Paulo; 2022; 64():e43. PubMed ID: 35730869 [No Abstract] [Full Text] [Related]
2. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination. Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers]. Çiçek K; Özkaya Y; Eser E; Buran ZC; Öztürk Arıkan ZÖ; Akçalı S; Erbay Dündar P; Cengiz Özyurt B; Şenol Akar Ş; Özer D; Karadağ Yalçın F Mikrobiyol Bul; 2023 Apr; 57(2):238-251. PubMed ID: 37067208 [TBL] [Abstract][Full Text] [Related]
4. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938 [TBL] [Abstract][Full Text] [Related]
5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
6. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ; Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136 [TBL] [Abstract][Full Text] [Related]
7. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022. Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708 [TBL] [Abstract][Full Text] [Related]
9. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178 [TBL] [Abstract][Full Text] [Related]
10. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults. Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants. Belik M; Jalkanen P; Lundberg R; Reinholm A; Laine L; Väisänen E; Skön M; Tähtinen PA; Ivaska L; Pakkanen SH; Häkkinen HK; Ortamo E; Pasternack A; Ritvos MA; Naves RA; Miettinen S; Sironen T; Vapalahti O; Ritvos O; Österlund P; Kantele A; Lempainen J; Kakkola L; Kolehmainen P; Julkunen I Nat Commun; 2022 May; 13(1):2476. PubMed ID: 35513437 [TBL] [Abstract][Full Text] [Related]
12. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880 [TBL] [Abstract][Full Text] [Related]
13. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Espino AM; Armina-Rodriguez A; Alvarez L; Ocasio-Malavé C; Ramos-Nieves R; Rodriguez Martinó EI; López-Marte P; Torres EA; Sariol CA Viruses; 2024 Jan; 16(2):. PubMed ID: 38399963 [TBL] [Abstract][Full Text] [Related]
14. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants. Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039 [TBL] [Abstract][Full Text] [Related]
15. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053 [TBL] [Abstract][Full Text] [Related]
16. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572 [TBL] [Abstract][Full Text] [Related]
18. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366 [TBL] [Abstract][Full Text] [Related]
19. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization. Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832 [TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection. Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]